Abstract: This disclosure provides antibody-urease conjugates having therapeutic and diagnostic utility. More specifically, the disclosure relates to diagnostic and/or therapeutic conjugates that are prepared by conjugating one or more whole antibodies to ease.

Abstract: The present invention relates to a method for producing a heat-treated food product from a food material which has been contacted with an asparaginase.

Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.

Abstract: A gene expression cassette capable of producing psicose at high yield with high stability, a GRAS (Generally recognized as safe) microorganism, a method of producing the enzyme by using the GRAS microorganism, and a method of producing the psicose by using the GRAS microorganism and enzyme are provided.

Abstract: A method for elevating a TRAIL-R1 expression in cancer cells to induce apoptosis. The method comprises the steps of receiving electrical energy having a specific voltage, frequency and power from an electrosurgical generator, up-converting the voltage and down-converting the frequency with a high voltage transformer having a primary coil and a secondary coil, the secondary coil having a larger number of turns than the primary coil, applying said converted electrical energy to an electrode in an electrosurgical hand piece, flowing an inert gas through said electrosurgical hand piece to produce a cold plasma at a distal end of said electrosurgical hand piece; and applying said cold plasma to cancer cells for 1 to 3 minutes. The inert gas may comprise, for example, helium or argon. In a preferred embodiment the cold plasma is applied to cancer cells for about 2 minutes.

Abstract: A container storage receptacle includes a package, a cleaning container that is enclosed and stored in the package, and that encloses and stores a cleaning solution for cleaning a nucleic acid binding activity solid-phase carrier which has an adsorbed nucleic acid, and an elution container that is enclosed and stored in the package, and that encloses and stores an eluent for eluting the nucleic acid from the nucleic acid binding activity solid-phase carrier. The cleaning solution and the eluent contain water, and an inner portion of the package is in a state of being saturated with water vapor.

Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

Abstract: Nucleic acid amplification tests have been widely used in clinical laboratories. Nucleic acid extraction from biological materials is challenging because different unfavorable substances may co-extract and inhibit downstream applications. The present invention relates to a composition of and a method for treating the sample prior, during or post extraction of nucleic acid. More specifically, the claimed invention relates to a composition of and a method for using low concentrations of common organic solvents to remove inhibitors of nucleic acid amplification. The present invention can be used for extracting nucleic acids (DNA/RNA) from bacteria, viruses, parasites, and other biological materials or matrices, including but not limit to, stool samples, body fluids, plants and cultures. The method is rapid, low-cost, and easy to use in a laboratory setting. The nucleic acid extracted in accordance with the invention can be used for nucleic acid amplification reactions.

Abstract: A parallel processing system for processing samples is described. In one embodiment, the parallel processing system includes an instrument interface parallel controller to control a tray motor driving system, a close-loop heater control and detection system, a magnetic particle transfer system, a reagent release system, a reagent pre-mix pumping system and a wash buffer pumping system.

Abstract: The invention relates to methods and compositions for estimating the absolute abundance individually for each unique rearranged lymphocyte receptor in a mixed sample.

Abstract: Methods, kits, and compositions of matter suitable for use in RNA Tagging are disclosed. In one embodiment, a method includes: expressing a fusion protein within the cellular environment, the fusion protein including at least part of the protein of interest and a tagging domain, the tagging domain introducing a selective tag to an RNA to which the fusion protein selectively binds, the selective tag including a selective tag sequence or a selective covalent modification; allowing the tagging domain to tag the RNA to which the protein of interest selectively binds by waiting for about 1 minute to about 28 days; and identifying the tagged RNA.

Abstract: Methods and manufactures for substantially unbiased amplification of genomes are provided herein. Some embodiments include methods of producing a substantially unbiased amplification library of a genome of a single cell. Some embodiments include methods of producing a substantially unbiased amplification of a genome by multiple strand displacement amplification (MDA).

Abstract: The present disclosure provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).

Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.

Abstract: This invention reveals a novel miRNA and a novel miRNA-regulated signaling network which controls brown adipogenesis and thermogenic programs, thereby providing a powerful approach for the treatment of obesity and related metabolic diseases. In this regard, the present invention is also directed towards methods of treatment of obesity and excess weight (overweight) and metabolic disorders caused by or aggravated by a subject being overweight or obese.

Abstract: The present invention relates to anti-miR-27b and anti-miR-148a oligonucleotides that are capable of decreasing the level and/or activity of miR-27b and miR-148a, respectively. In conjunction with the oligonucleotide molecules of the present invention, the invention also provides a method for decreasing the level and/or activity of miR-27b and/or miR-148a in a cell. In a further embodiment, the invention provides a method for treating a disease, especially dyslipidemias and cardiovascular diseases.

Abstract: The present disclosure relates to a method of preparing exonuclease resistant molecules of block-decoys, use of the molecules in methods of modulating expression of recombinant proteins, particularly in vitro, for example by down regulation or inhibition of one or more transcription factors, and novel molecules of block-decoys, especially those obtained or obtainable from the methods herein. The disclosure also relates to use of said block decoys in vitro and in therapy. In one aspect there is provided a method for regulating recombinant gene expression in vitro comprising the steps of: a) providing a host cell encoding one or more recombinant genes for expression, b) contacting the cell with a exonuclease resistant block-decoy under condition suitable for the block-decoy to gain entry into the cell, and c) expressing the recombinant protein or protein.

Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.

Abstract: Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity. Such improvements also include stability to serum nucleases, reduced binding to a soluble form of the target molecule, increased avidity, affinity or specificity to the target molecule on a cell surface, increased lifetime in circulation, or any combination of the foregoing. Improvements are provided by truncation, multimerization, including at least one non-natural nucleic acid, adding a 3? or 5? polyethylene glycol, or any combination thereof. Aptamers for treatment of autoimmune diseases are also provided.

Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNP), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

Abstract: [Problem] To provide a screening method for a substance having an anti-obesity action and an anti-obesity drug. Solution A screening method including: a step for contacting a test substance and a synoviolin-gene-expressing cell; and a step for verifying the effect of the test substance on the synoviolin gene expression, or the effect thereof on synoviolin protein activity. An action which reduces the amount of adipose tissue and an action which inhibits induction of adipocyte differentiation are examples of an anti-obesity action. An anti-obesity drug containing, as an active ingredient thereof, an siRNA of synoviolin, a decoy nucleic acid of synoviolin, or an antisense nucleic acid of synoviolin.

Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.

Abstract: This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity.

Abstract: Compositions and methods for treating diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mTORC1) are disclosed. The invention is based in part on the discovery that protein mediator of amino acid signaling to mTOR (MORTOR) is involved in amino acid-induced translocation of mTORC1 to lysosomes where MORTOR forms a signaling complex with mTORC1, Ragulator, and Rag GTPases, which controls protein synthesis. In particular, the invention relates to the use of antagonists of MORTOR for treating diseases and conditions associated with dysregulation of mTORC1. Downregulation of expression of MORTOR by RNA interference has been shown to reduce cell proliferation of cancerous cells and may be useful for treating cancer.

Abstract: Compositions comprising glucan-encapsulated siRNA directed against a region of the gene encoding the human CB1 receptor for use in the treatment of type 2 diabetes mellitus in a human subject. Additionally, methods for treating type 2 diabetes mellitus in a subject, comprising administering to the subject a composition comprising glucan-encapsulated siRNA directed against the CB1 receptor.

Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.

Abstract: The invention provides compositions and methods for clostridial bacteria that have been engineered to produce and/or to improve efficiency of production of industrial bioproducts.

Abstract: This disclosure provides Agrobacterium-mediated transformation methods for the oil-producing (oleaginous) yeast Lipomyces sp., as well as yeast produced by the method. Such methods utilize Agrobacterium sp. cells that have a T-DNA binary plasmid, wherein the T-DNA binary plasmid comprises a first nucleic acid molecule encoding a first protein and a second nucleic acid molecule encoding a selective marker that permits growth of transformed Lipomyces sp. cells in selective culture media comprising an antibiotic.

Abstract: It has been found that introducing into a Poaceae plant an Hd3a gene, which is a flower-bud-formation inducing gene, positioned downstream of a promoter whose expression is induced by a plant activator treatment makes it possible to control the flowering time of the Poaceae plant in accordance with a plant activator treatment timing. It has been found that further introducing a Ghd7 gene, which functions to suppress flower bud formation, into the plant makes it possible to suppress the expression of an endogenous Hd3a gene and increase the efficiency of controlling the flowering time.

Abstract: The present disclosure relates to methods and constructs for producing heterologous peptides and proteins in plants in a safe and controlled manner. One aspect of the present invention provides a method of producing heterologous protein in a transformed potato plant using an expression cassette comprising a gene coding for a protein or peptide of interest and a marker gene, a nucleotide sequence capable of suppressing patatin expression, along with a nucleotide sequence capable of suppressing CD4B expression, and/or a nucleotide sequence capable of overexpressing P19. Another aspect of the invention provides a method of producing a heterologous protein in a transformed potato plant using an expression cassette comprising a gene coding for a protein or peptide of interest, a marker gene, a transit peptide sequence, and a nucleotide sequence capable of suppressing ADP glucose pyrophosphorylase expression.

Abstract: The invention provides a novel MYB class transcription factor gene (nucleic acid sequences, protein sequences, and variants and fragments thereof) designated MYB14 by the applicants, that is useful for manipulating the production of flavonoids, specifically condensed tannins, in plants. The invention provides the isolated nucleic acid molecules encoding proteins with at least 70% identity to any one of MYB14 polypeptide sequences of SEQ ID NO: 14 and 46 to 54. The invention also provides, constructs, vectors, host cells, plant cells and plants genetically modified to contain the polynucleotide. The invention also provides methods for producing plants with altered flavonoid, specifically condensed tannin production, making use of the MYB14 nucleic acid molecules of the invention.

Abstract: Methods for consolidated pretreatment and hydrolysis of genetically engineered plants expressing cell wall degrading enzymes are provided. Expression cassettes and vectors for making transgenic plants are described. Plants engineered to express one or more cell wall degrading enzymes using expression cassettes and vectors of the invention are also provided.

Abstract: The present invention relates to a method for targeted inactivation of transcription factor using an artificial small interfering peptide and a use thereof. According to the present invention, an artificial small interfering peptide (a-siPEP) as a truncated from of the transcription factor for regulating transcription by dimerization was produced. It was also confirmed that, as a-siPEP forms a heterodimer with a transcription factor, DNA binding and transport into a nucleus of the transcription factor are inhibited, so that inactivation of the transcription factor is achieved at protein level. The method for inhibiting transcription factor activity using a-siPEP can replace a gene knock-out method and it allows protein-level inhibition of a transcription factor. Also, it is a transcription regulation method with high precision and high efficiency that can be applied for both monocot and dicot plants.

Abstract: A method for enhancing one or more yield-related traits in plants relative to control plants comprises modulating expression in a plant of a nucleic acid encoding a PAE1 (pectin acetylesterase) polypeptide. PAE1-encoding nucleic acids, and constructs comprising the same, are used in performing the method, and plants having one or more enhanced yield-related traits are obtained.

Abstract: This invention relates to methods for producing plants having an increased number of seeds and methods for producing plants having increased assimilate partitioning directed into fruits, seeds and/or other plant part (e.g., roots and/or tubers), and/or increased seed, root and/or tuber size, or any combination thereof.

Abstract: Provided are methods of increasing the tolerance of a plant to abiotic stresses and/or increasing the biomass and/or increasing the yield of a plant by expressing within the plant an exogenous polynucleotide encoding a polypeptide homologous to SEQ ID NO:240, such as the polynucleotide set forth by SEQ ID NO:14.

Abstract: Materials and methods for making plants (e.g., Brassica varieties) with tolerance to ALS-inhibiting herbicides are provided herein. The methods can include making mutations in the gene encoding acetolactate synthase (ALS)/acetohydroxyacid synthase (AHAS), where the mutations are induced using a rare-cutting endonuclease and a donor matrix.

Abstract: The present invention relates to the identification of the xcv-1 gene, which is responsible for a recessive resistance to Xanthomonas euvesicatoria, by genetic mapping-based cloning from Capsicum annuum. In addition, the invention relates to methods for generating plants resistant to an abiotic or biotic factor, in particular to Xanthomonas euvesicatoria, and the plants themselves, in particular tomato plants.

Abstract: The present invention relates to a transgenic plant which has integrated into its genome an exogenous polynucleotide encoding a polypeptide which confers resistance to Puccinia graminis f sp. tritici, such as the Ug99 group of races Puccinia graminis f. sp. tritici. In an embodiment, the polynucleotide is the Sr33 gene from Aegilops tauschii.

Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 by having at least 70% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in ON bipolar cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.

Abstract: Provided are novel compositions useful for delivering nucleic acids to cells. Also provided are methods for making and using such compositions.

Abstract: The disclosure provides compositions and methods for increasing efficiency of Cas9-mediated target DNA modification. Specifically, the disclosure provides compositions and methods for carrying out site-directed modification of a target DNA, the methods comprising contacting the target DNA with: a) a complex comprising a Cas9 polypeptide and a guide RNA, and b) a Rad51 polypeptide. The site-directed modification of a target DNA can be carried out in a living cell in vitro, in a living cell in vivo, or in a cell-free system in vitro.

Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification in mammalian cells. The present specification describes the design and testing of a polynucleotide encoding the Streptococcus pyogenes (S. pyogenes) Cas9 protein, where the nucleotide sequence has been optimized for expression in mammalian cells. The specification also describes all-in-one systems for RNA-guided genome engineering in mammalian cells, including human cells.

Abstract: The present invention is in the field of the gene editing molecular tools. The present invention relates to rewritten nucleic acid sequences encoding repeated DNA recognition motifs of TALE (Transcription Activator-Like Effector) proteins. These nucleic acid sequences allow assembly and cloning of TALE repeats in any type of vectors, especially viral vectors. The invention thereby contributes to improving gene targeting in cells using TALE derived proteins, in particular for genetic regulation or modification. The present invention is particularly drawn to virus mediated transformation methods, by providing vectors, compositions and kits including said new nucleic acid sequences.

Abstract: The present invention provides a method for generating methane from a carbonaceous feedstock with simultaneous in situ sequestration of carbon dioxide to afford a biogas comprising at least 85 percent by volume methane, the method comprising anaerobically incubating a particulate additive in contact with a carbonaceous feedstock in a neutral or alkaline aqueous culture medium containing a culture of methanogenic consortia and collecting methane generated therefrom. The additive comprises at least one material selected from a biochar, an ash produced by gasification or combustion of a carbonaceous material, a black carbon soil, and a Terra Preta soil.

Abstract: Provided herein are metabolically-modified microorganisms useful for producing biofuels. More specifically, provided herein are methods of producing high alcohols including isobutanol, 1-butanol, 1-propanol, 2-methyl-1-butanol, 3-methyl-1-butanol and 2-phenylethanol from a suitable substrate.

Abstract: Provided herein are recombinant yeast host cells and methods for their use for production of fermentation products from a pyruvate utilizing pathway. The yeast host cells provided herein comprise at least one genetic modification in a pyruvate decarboxylase gene and at least one genetic modification in an endogenous cell wall protein, which confers resistance to butanol and increased glucose utilization.

Abstract: Provided herein are metabolically-modified microorganisms useful for producing biofuels. More specifically, provided herein are methods of producing high alcohols including isobutanol, 1-butanol, 1-propanol, 2-methyl-1-butanol, 3-methyl-1-butanol, and 2-phenylethanol from a suitable substrate and a recombinant acetolactate synthase having both synthase and decarboxylase activity.